Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues
Executive Summary
Increased confidence in Elan/Biogen's ability to return the multiple sclerosis therapy Tysabri to the market by the fall could be a signal that pharma and biotech companies have turned the corner on drug safety issues
You may also be interested in...
Bristol $300 Mil. DoJ Settlement Includes Separation OF CEO/Chairman Roles
Bristol-Myers Squibb board member James Robinson will take on additional corporate governance oversight responsibilities, including meeting with execs prior to analyst calls, as the newly-appointed chairman
Bristol’s DTC Moratorium Will Affect Muraglitazar, Abatacept Launches
Muraglitazar and abatacept are likely to be the first Bristol-Myers Squibb products significantly affected by the company's recent moratorium on direct-to-consumer advertising during a drug's first 12 months on the market
Merck Taps Clark As CEO In Nod To Medco Heritage; Gilmartin To Retire
Merck's appointment of Richard Clark to succeed retiring CEO Ray Gilmartin continues the Medco legacy at Merck's senior management level